Levothyroxine (T4) is a critical-dose drug, because little variations in the blood concentration may cause treatment failure as well as iatrogenic thyrotoxicosis. Despite the dose response of this drug being more carefully titrated nowadays, several papers still report that a significant fraction of patients treated with levothyroxine demonstrate a TSH which is not on target. Moreover, some widespread gastrointestinal disorders as well as interfering drugs and foods may cause the “refractoriness” of a significant number of patients to an expected dose of thyroxine. The increasing awareness of the mechanisms interfering with the oral thyroid hormone bioavailability and the body of evidence regarding the complexity of treatment in certain classes of patients prompted pharmaceutical research to identify new hormonal formulations to optimize the performance of this drug. In this brief review, the progression of the scientific knowledge of novel T4 formulations use has been analyzed.

Novel thyroxine formulations. A further step toward precision medicine / Virili, Camilla; Pierpaolo, Trimboli; Centanni, Marco. - In: ENDOCRINE. - ISSN 1559-0100. - 1:66(2019), pp. 87-94. [10.1007/s12020-019-02049-x]

Novel thyroxine formulations. A further step toward precision medicine

Virili Camilla;Marco Centanni
2019

Abstract

Levothyroxine (T4) is a critical-dose drug, because little variations in the blood concentration may cause treatment failure as well as iatrogenic thyrotoxicosis. Despite the dose response of this drug being more carefully titrated nowadays, several papers still report that a significant fraction of patients treated with levothyroxine demonstrate a TSH which is not on target. Moreover, some widespread gastrointestinal disorders as well as interfering drugs and foods may cause the “refractoriness” of a significant number of patients to an expected dose of thyroxine. The increasing awareness of the mechanisms interfering with the oral thyroid hormone bioavailability and the body of evidence regarding the complexity of treatment in certain classes of patients prompted pharmaceutical research to identify new hormonal formulations to optimize the performance of this drug. In this brief review, the progression of the scientific knowledge of novel T4 formulations use has been analyzed.
2019
drugs dissolution; gastrointestinal disorders; liquid levothyroxine; softgel thyroxine; thyroxine absorption; thyroxine malabsorption.
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Novel thyroxine formulations. A further step toward precision medicine / Virili, Camilla; Pierpaolo, Trimboli; Centanni, Marco. - In: ENDOCRINE. - ISSN 1559-0100. - 1:66(2019), pp. 87-94. [10.1007/s12020-019-02049-x]
File allegati a questo prodotto
File Dimensione Formato  
Virili_Novel-thyroxine-formulations_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 701.34 kB
Formato Adobe PDF
701.34 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1449136
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 21
social impact